1 NovoLog<sup>®</sup>

# 2 Insulin aspart (rDNA origin) Injection

3 4

5

# DESCRIPTION

6 NovoLog<sup>®</sup> (insulin aspart [rDNA origin] injection) is a human insulin analog that is a rapid-


7 acting, parenteral blood glucose-lowering agent. NovoLog is homologous with regular human

8 insulin with the exception of a single substitution of the amino acid proline by aspartic acid in

9 position B28, and is produced by recombinant DNA technology utilizing *Saccharomyces* 

10 *cerevisiae* (baker's yeast) as the production organism. Insulin aspart has the empirical formula

- 11  $C_{256}H_{381}N_{65}0_{79}S_6$  and a molecular weight of 5825.8.
- 12



13

14 Figure 1. Structural formula of insulin aspart.

15

16 NovoLog is a sterile, aqueous, clear, and colorless solution, that contains insulin aspart (B28

17 asp regular human insulin analog) 100 Units/mL, glycerin 16 mg/mL, phenol 1.50 mg/mL,

18 metacresol 1.72 mg/mL, zinc 19.6 µg/mL, disodium hydrogen phosphate dihydrate 1.25

19 mg/mL, and sodium chloride 0.58 mg/mL. NovoLog has a pH of 7.2-7.6. Hydrochloric acid

20 10% and/or sodium hydroxide 10% may be added to adjust pH.

21

# 22 CLINICAL PHARMACOLOGY

# 23 Mechanism of Action

24 The primary activity of NovoLog is the regulation of glucose metabolism. Insulins, including

25 NovoLog, bind to the insulin receptors on muscle and fat cells and lower blood glucose by

26 facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose

- 27 from the liver.
- 28

29 In standard biological assays in mice and rabbits, one unit of NovoLog has the same glucose-

30 lowering effect as one unit of regular human insulin. In humans, the effect of NovoLog is

31 more rapid in onset and of shorter duration, compared to regular human insulin, due to its

32 faster absorption after subcutaneous injection (see Figure 2 and Figure 3).

33

#### 34 Pharmacokinetics


- 35 The single substitution of the amino acid proline with aspartic acid at position B28 in
- 36 NovoLog reduces the molecule's tendency to form hexamers as observed with regular human
- 37 insulin. NovoLog is, therefore, more rapidly absorbed after subcutaneous injection compared
- 38 to regular human insulin.
- 39

40 Bioavailability and Absorption - NovoLog has a faster absorption, a faster onset of action,

and a shorter duration of action than regular human insulin after subcutaneous injection (see

42 Figure 2 and Figure 3). The relative bioavailability of NovoLog compared to regular human

43 in sulin indicates that the two insulins are absorbed to a similar extent. 44  $\stackrel{\subseteq}{=}$ 



45 46

47 Figure 2. Serial mean serum free insulin concentration collected up to 6 hours following a

48 single pre-meal dose of NovoLog (solid curve) or regular human insulin (hatched curve)

49 injected immediately before a meal in 22 patients with Type 1 diabetes.

50

51 In studies in healthy volunteers (total n=107) and patients with Type 1 diabetes (total n=40),

52 NovoLog consistently reached peak serum concentrations approximately twice as fast as

regular human insulin. The median time to maximum concentration in these trials was 40 to

54 50 minutes for NovoLog versus 80 to 120 minutes for regular human insulin. In a clinical trial

55 in patients with Type 1 diabetes, NovoLog and regular human insulin, both administered

subcutaneously at a dose of 0.15 U/kg body weight, reached mean maximum concentrations of

57 82.1 and 35.9 mU/L, respectively. Pharmacokinetic/pharmacodynamic characteristics of

insulin aspart have not been established in patients with Type 2 diabetes.

59 The intra-individual variability in time to maximum serum insulin concentration for healthy

60 male volunteers was significantly less for NovoLog than for regular human insulin. The

61 clinical significance of this observation has not been established.

62 In a clinical study in healthy non-obese subjects, the pharmacokinetic differences between

63 NovoLog and regular human insulin described above, were observed independent of the

64 injection site (abdomen, thigh, or upper arm). Differences in pharmacokinetics between

- NovoLog and regular human insulin are not associated with differences in overall glycemic
- 66 control.


#### 67

- 68 Distribution and Elimination NovoLog has a low binding to plasma proteins, 0-9%, similar
- 69 to regular human insulin. After subcutaneous administration in normal male volunteers
- 70 (n=24), NovoLog was more rapidly eliminated than regular human insulin with an average
- apparent half-life of 81 minutes compared to 141 minutes for regular human insulin.
- 72

### 73 Pharmacodynamics

- Studies in normal volunteers and patients with diabetes demonstrated that NovoLog has amore rapid onset of action than regular human insulin.
- In a 6-hour study in patients with Type 1 diabetes (n=22), the maximum glucose-lowering
- effect of NovoLog occurred between 1 and 3 hours after subcutaneous injection (see Figure 3).
- 78 The duration of action for NovoLog is 3 to 5 hours compared to 5 to 8 hours for regular human
- <sup>79</sup> insulin. The time course of action of insulin and insulin analogs such as NovoLog may vary
- 80 considerably in different individuals or within the same individual. The parameters of
- 81 NovoLog activity (time of onset, peak time and duration) as designated in Figure 3 should be
- considered only as general guidelines. The rate of insulin absorption and consequently the
- onset of activity is known to be affected by the site of injection, exercise, and other variables
- 84 (see PRECAUTIONS, General). Differences in pharmacodynamics between NovoLog and
- regular human insulin are not associated with differences in overall glycemic control.





87 88

Figure 3. Serial mean serum glucose collected up to 6 hours following a single pre-meal dose
of NovoLog (solid curve) or regular human insulin (hatched curve) injected immediately
before a meal in 22 patients with Type 1 diabetes.

before a meal in 22 patients with Type 1 92

### 93 Special Populations

- **Children and Adolescents** The pharmacokinetic and pharmacodynamic properties of NovoLog and regular human insulin were evaluated in a single dose study in 18 children (6-12 years, n=9) and adolescents (13-17 years [Tanner grade  $\geq 2$ ], n=9) with Type 1 diabetes. The relative differences in pharmacokinetics and pharmacodynamics in children and adolescents with Type 1 diabetes between NovoLog and regular human insulin were similar to those in
- 99 healthy adult subjects and adults with Type 1 diabetes.

- 100
   101 *Geriatrics* The effect of age on the pharmacokinetics and pharmacodynamics of NovoLog
   102 has not been studied.
- 103

104 *Gender* - In healthy volunteers, no difference in insulin aspart levels was seen between men
 105 and women when body weight differences were taken into account. There was no significant
 106 difference in efficacy noted (as assessed by HbAlc) between genders in a trial in patients with
 107 Type 1 diabetes.

108

109 **Obesity** - In a study of 23 patients with type 1 diabetes and a wide range of body mass index

110 (BMI, 22-39 kg/m<sup>2</sup>), the pharmacokinetic parameters, AUC and Cmax, of NovoLog were

111 generally unaffected by BMI. Clearance of NovoLog was reduced by 28% in patients with

BMI >32 compared to patients with BMI <23 when a single dose of 0.1 U/kg NovoLog was administered. However, only 3 patients with BMI <23 were studied.

114

*Ethnic Origin* - The effect of ethnic origin on the pharmacokinetics of NovoLog has not beenstudied.

117

118 *Renal Impairment* - Some studies with human insulin have shown increased circulating

119 levels of insulin in patients with renal failure. A single subcutaneous dose of NovoLog was

administered in a study of 18 patients with creatinine clearance values ranging from normal to

121 <30 mL/min and not requiring hemodialysis. No apparent effect of creatinine clearance values

122 on AUC and Cmax of NovoLog was found. However, only 2 patients with severe renal

123 impairment were studied (<30 mL/min). Careful glucose monitoring and dose adjustments of

insulin, including NovoLog, may be necessary in patients with renal dysfunction (see

125 PRECAUTIONS, Renal Impairment).

126

127 Hepatic Impairment - Some studies with human insulin have shown increased circulating

levels of insulin in patients with liver failure. In an open-label, single-dose study of 24

129 patients with Child-Pugh Scores ranging from 0 (healthy volunteers) to 12 (severe hepatic

impairment), no correlation was found between the degree of hepatic failure and any NovoLog

131 pharmacokinetic parameter. Careful glucose monitoring and dose adjustments of insulin, 122 including Nevel ag may be necessary in patients with hepatic dysfunction (cos

including NovoLog, may be necessary in patients with hepatic dysfunction (seePRECAUTIONS, Hepatic Impairment).

133 P 134

135 *Pregnancy* - The effect of pregnancy on the pharmacokinetics and glucodynamics of

136 NovoLog has not been studied (see PRECAUTIONS, Pregnancy).

137

138 Smoking - The effect of smoking on the pharmacokinetics/pharmacodynamics of NovoLog

has not been studied.

# 140141 CLINICAL STUDIES

142 To evaluate the safety and efficacy of NovoLog in patients with Type 1 diabetes, two

143 six-month, open-label, active-control (NovoLog vs. Novolin<sup>®</sup> R) studies were conducted (see

144 Table 1). NovoLog was administered by subcutaneous injection immediately prior to meals

- 145 and regular human insulin was administered by subcutaneous injection 30 minutes before
- 146 meals. NPH insulin was administered as the basal insulin in either single or divided daily
- 147 doses. Changes in HbA1c, the rates of hypoglycemia (as determined from the number of
- events requiring intervention from a third party), and the incidence of ketosis were clinically
- 149 comparable for the two treatment regimens. The mean total daily doses of insulin were greater
- 150 (1-3 U/day) in the NovoLog-treated patients compared to patients who received regular human
- insulin. This difference was primarily due to basal insulin requirements. To achieve
- 152 improved glycemic control, some patients required more than three doses of meal-related
- insulin and/or more than one dose of basal insulin (see Table 1). No serum glucose
- 154 measurements were obtained in these studies.
- 155

To evaluate the safety and efficacy of NovoLog in patients with Type 2 diabetes, one six-

- 157 month, open-label, active-control (NovoLog vs. Novolin R) study was conducted (see Table
- 158 1). NovoLog was administered by subcutaneous injection immediately prior to meals and
- regular human insulin was administered by subcutaneous injection 30 minutes before meals.
- 160 NPH insulin was administered as the basal insulin in either single or divided daily doses.
- 161 Changes in HbAlc and the rates of hypoglycemia (as determined from the number of events
- 162 requiring intervention from a third party) were clinically comparable for the two treatment
- regimens. The mean total daily dose of insulin was greater (2 U/day) in the NovoLog-treated
- 164 patients compared to patients who received regular human insulin. This difference was
- primarily due to basal insulin requirements. To achieve improved glycemic control, some patients required more than three doses of meal-related insulin and/or more than one dose of
- patients required more than three doses of meal-related insulin and/or morebasal insulin (see Table 1).
- 167 basal insulin (see Table168
- 169 Table 1. Results of two six-month, active-control, open-label trials in patients with Type 1
- diabetes (Studies A and B) and one six-month, active-control, open-label trial in patients with
   Type 2 diabetes (Study C).
- 172

Study	Treatment (n)	Mean HbA1c (%) Baseline Month		Hypoglycemia <sup>1</sup> (events / month / patient)		% of Patients Using Various Numbers of Insulin Injections / Day <sup>2</sup>			
				r r · · · · ·	Rapid-acting			Basal	
			6		1 - 2	3	4 - 5	1	2
А	NovoLog (n=694)	8.0	7.9	0.06	3	75	22	54	46
	Novolin R (n=346)	8.0	8.0	0.06	6	75	19	63	37
В	NovoLog (n=573)	7.9	7.8	0.08	4	90	6	94	6
	Novolin R (n=272)	8.0	7.9	0.06	4	91	4	93	7
С	NovoLog (n=90)	8.1	7.7	0.02	4	93	4	97	4
	Novolin R (n=86)	7.8	7.8	0.01	2	93	5	93	7

<sup>1</sup> Events requiring intervention from a third party during the last three months of treatment

<sup>2</sup> Percentages are rounded to the nearest whole number

175

176 To evaluate the use of NovoLog by subcutaneous infusion with an external pump, two open-

177 label, parallel design studies (6 weeks [n=29] and 16 weeks [n=118]) compared NovoLog

178 versus Velosulin<sup>®</sup> (buffered regular human insulin) in patients with Type 1 diabetes. Changes

- in HbA1c and rates of hypoglycemia were comparable. Patients with Type 2 diabetes were
- also studied in an open-label, parallel design trial (16 weeks [n=127]) using NovoLog by
- 181 subcutaneous infusion compared to pre-prandial injection (in conjunction with basal NPH
- 182 injections). Reductions in HbA1c and rates of hypoglycemia were comparable. (See
- 183 INDICATIONS AND USAGE, WARNINGS, PRECAUTIONS, Mixing of Insulins,
- 184 Information for Patients, DOSAGE AND ADMINISTRATION, and RECOMMENDED
- 185 STORAGE.)
- 186

# 187 INDICATIONS AND USAGE

NovoLog is indicated for the treatment of adult patients with diabetes mellitus, for the control of hyperglycemia. Because NovoLog has a more rapid onset and a shorter duration of activity than human regular insulin, NovoLog given by injection should normally be used in regimens

- with an intermediate or long-acting insulin. NovoLog may also be infused subcutaneously by
- external insulin pumps. (See WARNINGS, PRECAUTIONS [especially Usage in Pumps],
- Information for Patients [especially For Patients Using Pumps], Mixing of Insulins, DOSAGE
- 194 AND ADMINISTRATION, RECOMMENDED STORAGE.)

# 196 CONTRAINDICATIONS

NovoLog is contraindicated during episodes of hypoglycemia and in patients hypersensitive toNovoLog or one of its excipients.

199

195

# 200 WARNINGS

- 201 NovoLog differs from regular human insulin by a more rapid onset and a shorter
- 202 duration of activity. Because of the fast onset of action, the injection of NovoLog should
- 203 immediately be followed by a meal. Because of the short duration of action of NovoLog,
- 204 patients with diabetes also require a longer-acting insulin to maintain adequate glucose
- 205 control. Glucose monitoring is recommended for all patients with diabetes and is
- 206 particularly important for patients using external pump infusion therapy.
- 207
- 208 Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog.
- As with all insulins, the timing of hypoglycemia may differ among various insulin formulations.
- 210 for211
- 212 Any change of insulin dose should be made cautiously and only under medical
- supervision. Changes in insulin strength, manufacturer, type (e.g., regular, NPH,
- analog), species (animal, human), or method of manufacture (rDNA versus animal-
- source insulin) may result in the need for a change in dosage.
- 216
- 217 Insulin Pumps: When used in an external insulin pump for subcutaneous infusion,
- 218 NovoLog should not be diluted or mixed with any other insulin. Physicians and patients
- 219 should carefully evaluate information on pump use in the NovoLog physician and patient
- 220 package inserts and in the pump manufacturer's manual (e.g. NovoLog-specific
- 221 information should be followed for in-use time, frequency of changing infusion sets, or
- 222 other details specific to NovoLog usage, because NovoLog-specific information may
- 223 differ from general pump manual instructions). Pump or infusion set malfunctions or

- insulin degradation can lead to hyperglycemia and ketosis in a short time because of the
- small subcutaneous depot of insulin. This is especially pertinent for rapid-acting insulin
- 226 analogs that are more rapidly absorbed through skin and have shorter duration of
- 227 action. These differences may be particularly relevant when patients are switched from
- multiple injection therapy or infusion with buffered regular insulin. Prompt
- 229 identification and correction of the cause of hyperglycemia or ketosis is necessary.
- 230 Interim therapy with subcutaneous injection may be required. (See PRECAUTIONS,
- 231 Mixing of Insulins, Information for Patients, DOSAGE AND ADMINISTRATION, and
- 232 RECOMMENDED STORAGE.)
- 233

## 234 **PRECAUTIONS**

#### 235 General

- 236 Hypoglycemia and hypokalemia are among the potential clinical adverse effects associated
- with the use of all insulins. Because of differences in the action of NovoLog and other
- insulins, care should be taken in patients in whom such potential side effects might be
- clinically relevant (e.g., patients who are fasting, have autonomic neuropathy, or are using
- 240 potassium-lowering drugs or patients taking drugs sensitive to serum potassium level).
- 241 Lipodystrophy and hypersensitivity are among other potential clinical adverse effects
- associated with the use of all insulins.
- As with all insulin preparations, the time course of NovoLog action may vary in different
- individuals or at different times in the same individual and is dependent on site of injection,
- blood supply, temperature, and physical activity.
- Adjustment of dosage of any insulin may be necessary if patients change their physical
- 247 activity or their usual meal plan. Insulin requirements may be altered during illness,
- 248 emotional disturbances, or other stresses.
- 249
- 250 Hypoglycemia As with all insulin preparations, hypoglycemic reactions may be associated
- with the administration of NovoLog. Rapid changes in serum glucose levels may induce
- symptoms of hypoglycemia in persons with diabetes, regardless of the glucose value. Early
- warning symptoms of hypoglycemia may be different or less pronounced under certain
- conditions, such as long duration of diabetes, diabetic nerve disease, use of medications such
- as beta-blockers, or intensified diabetes control (see PRECAUTIONS, Drug Interactions).
- Such situations may result in severe hypoglycemia (and, possibly, loss of consciousness) priorto patients' awareness of hypoglycemia.
- 257 to patients' aw258
- 259 **Renal Impairment** As with other insulins, the dose requirements for NovoLog may be
- 260 reduced in patients with renal impairment (see CLINICAL PHARMACOLOGY,
- 261 Pharmacokinetics).
- 262
- 263 *Hepatic Impairment* As with other insulins, the dose requirements for NovoLog may be
- reduced in patients with hepatic impairment (see CLINICAL PHARMACOLOGY,
- 265 Pharmacokinetics).
- 266
- Allergy Local Allergy As with other insulin therapy, patients may experience redness,
   swelling, or itching at the site of injection. These minor reactions usually resolve in a few

- 269 days to a few weeks, but in some occasions, may require discontinuation of NovoLog. In
- some instances, these reactions may be related to factors other than insulin, such as irritants in a skin cleansing agent or poor injection technique.
- a skin cleansing agent of poor injection to
- 273 **Systemic Allergy** Less common, but potentially more serious, is generalized allergy to
- insulin, which may cause rash (including pruritus) over the whole body, shortness of breath,
- 275 wheezing, reduction in blood pressure, rapid pulse, or sweating. Severe cases of generalized
- allergy, including anaphylactic reaction, may be life threatening.
- Localized reactions and generalized myalgias have been reported with the use of cresol as aninjectable excipient.
- In controlled clinical trials using injection therapy, allergic reactions were reported in 3 of 735
- patients (0.4%) who received regular human insulin and 10 of 1394 patients (0.7%) who
- received NovoLog. During these and other trials, 3 of 2341 patients treated with NovoLog
- were discontinued due to allergic reactions.
- 283
- 284 Antibody Production Increases in levels of anti-insulin antibodies that react with both
- human insulin and insulin aspart have been observed in patients treated with NovoLog. The
- number of patients treated with insulin aspart experiencing these increases is greater than the
- number among those treated with human regular insulin. Data from a 12-month controlled
- trial in patients with Type 1 diabetes suggest that the increase in these antibodies is transient.
- The differences in antibody levels between the human regular insulin and insulin aspart
- treatment groups observed at 3 and 6 months were no longer evident at 12 months. The clinical significance of these antibodies is not known. They do not appear to cause
- deterioration in HbA1c or to necessitate increases in insulin dose.
- 293

#### 294 Pregnancy and Lactation

- 295 Female patients should be advised to tell their physician if they intend to become, or if they
- become pregnant. Information is not available on the use of NovoLog during pregnancy orlactation.
- 298
- 299 Usage in Pumps
- 300 NovoLog is recommended for use in Disetronic H-TRON<sup>®</sup> plus V100 with Disetronic 3.15
- plastic cartridges and Classic or Tender infusion sets; MiniMed Models 505, 506, or 507 with
   MiniMed 3 mL syringes and Polyfin<sup>®</sup> or Sof-set<sup>®</sup> infusion sets.
- 303

304 In-vitro studies have shown that pump malfunction, loss of cresol, and insulin degradation,

- may occur with the use of NovoLog for more than two days at  $37^{\circ}C$  (98.6°F) in infusion sets
- and reservoirs. NovoLog in clinical use should not be exposed to temperatures greater than
- 307 37°C (98.6°F). NovoLog should not be mixed with other insulins or with a diluent when it
- is used in the pump. (See WARNINGS, PRECAUTIONS, Mixing of Insulins, Information
- 309 for Patients, DOSAGE AND ADMINISTRATION, and RECOMMENDED STORAGE.)
- 310
- 311
- 312 Information for Patients
- 313 For all patients:

- 314 Patients should be informed about potential risks and advantages of NovoLog therapy
- including the possible side effects. Patients should also be offered continued education and
- advice on insulin therapies, injection technique, life-style management, regular glucose
- 317 monitoring, periodic glycosylated hemoglobin testing, recognition and management of hypo-
- and hyperglycemia, adherence to meal planning, complications of insulin therapy, timing of
- dose, instruction in the use of injection or subcutaneous infusion devices, and proper storage
- 320 of insulin. Patients should be informed that frequent, patient-performed blood glucose
- 321 measurements are needed to achieve optimal glycemic control and avoid both hyper- and
- 322 hypoglycemia.323
- 324 Female patients should be advised to tell their physician if they intend to become, or if they
- 325 become pregnant. Information is not available on the use of NovoLog during pregnancy or
- 326 lactation (see PRECAUTIONS, Pregnancy).
- 327

### 328 For patients using pumps:

- 329 Patients using external pump infusion therapy should be trained in intensive insulin therapy
- 330 with multiple injections and in the function of their pump and pump accessories. NovoLog is
- 331 recommended for use with Disetronic H-TRON plus V100 with Disetronic 3.15 plastic
- cartridges and Classic or Tender infusion sets; MiniMed Models 505, 506, and 507 with
- 333 MiniMed 3 mL syringes and Polyfin or Sof-set infusion sets. The use of NovoLog in quick-
- release infusion sets and cartridge adapters has not been assessed.
- 335
- 336 To avoid insulin degradation, infusion set occlusion, and loss of the preservative (cresol),
- 337 the infusion sets (reservoir syringe, tubing, and catheter) and the NovoLog in the
- reservoir should be replaced, and a new infusion site selected every 48 hours or less.
- 339 Insulin exposed to temperatures higher than 37°C (98.6°F) should be discarded. The
- temperature of the insulin may exceed ambient temperature when the pump housing, cover,
- tubing, or sport case is exposed to sunlight or radiant heat. Infusion sites that are
- 342 erythematous, pruritic, or thickened should be reported to medical personnel, and a new site
- 343 selected because continued infusion may increase the skin reaction and/or alter the absorption 344 of NovoLog.
- 345
- <sup>346</sup> Pump or infusion set malfunctions or insulin degradation can lead to hyperglycemia and
- 347 ketosis in a short time because of the small subcutaneous depot of insulin. This is especially
- 348 pertinent for rapid-acting insulin analogs that are more rapidly absorbed through skin and have
- 349 shorter duration of action. These differences are particularly relevant when patients are
- 350 switched from infused buffered regular insulin or multiple injection therapy. Prompt
- identification and correction of the cause of hyperglycemia or ketosis is necessary. Problems
- include pump malfunction, infusion set occlusion, leakage, disconnection or kinking, and
- degraded insulin. Less commonly, hypoglycemia from pump malfunction may occur. If these
- problems cannot be promptly corrected, patients should resume therapy with subcutaneous
- insulin injection and contact their physician. (See WARNINGS, PRECAUTIONS, Mixing of
- 356 Insulins, DOSAGE AND ADMINISTRATION, and RECOMMENDED STORAGE.)
- 357
- 358 Laboratory Tests

- As with all insulin therapy, the therapeutic response to NovoLog should be monitored by
- 360 periodic blood glucose tests. Periodic measurement of glycosylated hemoglobin is
- 361 recommended for the monitoring of long-term glycemic control.
- 362

# 363 Drug Interactions

A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.

- The following are examples of substances that may increase the blood-glucose-lowering
   effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors,
   disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene,
   salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
- The following are examples of substances that may reduce the blood-glucose-lowering
  effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g.,
  epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin,
  thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
- Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the
   blood-glucose-lowering effect of insulin. Pentamidine may cause hypoglycemia, which
   may sometimes be followed by hyperglycemia.
- In addition, under the influence of sympatholytic medicinal products such as beta blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be
   reduced or absent (see CLINICAL PHARMACOLOGY).

# 381 Mixing of Insulins

- A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog
   with NPH human insulin immediately before injection produced some attenuation in the
   peak concentration of NovoLog, but that the time to peak and the total bioavailability of
   NovoLog were not significantly affected. If NovoLog is mixed with NPH human insulin,
- NovoLog were not significantly affected. If NovoLog is mixed with NPH human insu NovoLog should be drawn into the syringe first. The injection should be made
- immediately after mixing. Because there are no data on the compatibility of NovoLog and
   crystalline zinc insulin preparations, NovoLog should not be mixed with these
   preparations.
- The effects of mixing NovoLog with insulins of animal source or insulin preparations
   produced by other manufacturers have not been studied (see WARNINGS).
- Mixtures should not be administered intravenously.
- When used in external subcutaneous infusion pumps for insulin, NovoLog should not be
   mixed with any other insulins or diluent.
- 395

380

# 396 Carcinogenicity, Mutagenicity, Impairment of Fertility

397 Standard 2-year carcinogenicity studies in animals have not been performed to evaluate the 398 carcinogenic potential of NovoLog. In 52-week studies, Sprague-Dawley rats were dosed

- subcutaneously with NovoLog at 10, 50, and 200 U/kg/day (approximately 2, 8, and 32 times
- the human subcutaneous dose of 1.0 U/kg/day, based on U/body surface area, respectively).
- At a dose of 200 U/kg/day, NovoLog increased the incidence of mammary gland tumors in
- females when compared to untreated controls. The incidence of mammary tumors for
- 403 NovoLog was not significantly different than for regular human insulin. The relevance of

- 404 these findings to humans is not known. NovoLog was not genotoxic in the following tests:
- Ames test, mouse lymphoma cell forward gene mutation test, human peripheral blood 405
- lymphocyte chromosome aberration test, in vivo micronucleus test in mice, and in ex vivo 406
- UDS test in rat liver hepatocytes. In fertility studies in male and female rats, at subcutaneous 407
- doses up to 200 U/kg/day (approximately 32 times the human subcutaneous dose, based on 408
- U/body surface area), no direct adverse effects on male and female fertility, or general 409
- reproductive performance of animals was observed. 410
- 411

#### Pregnancy - Teratogenic Effects - Pregnancy Category C 412

- 413 There are no adequate well-controlled clinical studies of the use of NovoLog in pregnant
- 414 women. NovoLog should be used during pregnancy only if the potential benefit justifies the
- 415 potential risk to the fetus.
- 416
- It is essential for patients with diabetes or history of gestational diabetes to maintain good 417
- metabolic control before conception and throughout pregnancy. Insulin requirements may 418
- decrease during the first trimester, generally increase during the second and third trimesters, 419
- 420 and rapidly decline after delivery. Careful monitoring of glucose control is essential in such patients.
- 421
- 422 423 Subcutaneous reproduction and teratology studies have been performed with NovoLog and
- 424 regular human insulin in rats and rabbits. In these studies, NovoLog was given to female rats
- before mating, during mating, and throughout pregnancy, and to rabbits during organogenesis. 425
- The effects of NovoLog did not differ from those observed with subcutaneous regular human 426
- 427 insulin, NovoLog, like human insulin, caused pre- and post-implantation losses and
- visceral/skeletal abnormalities in rats at a dose of 200 U/kg/day (approximately 32 times the 428
- 429 human subcutaneous dose of 1.0 U/kg/day, based on U/body surface area) and in rabbits at a
- 430 dose of 10 U/kg/day (approximately three times the human subcutaneous dose of 1.0
- U/kg/day, based on U/body surface area). The effects are probably secondary to maternal 431
- hypoglycemia at high doses. No significant effects were observed in rats at a dose of 50 432
- U/kg/day and rabbits at a dose of 3 U/kg/day. These doses are approximately 8 times the 433
- 434 human subcutaneous dose of 1.0 U/kg/day for rats and equal to the human subcutaneous dose
- of 1.0 U/kg/day for rabbits, based on U/body surface area. 435
- 436

#### 437 **Nursing Mothers**

- 438 It is unknown whether insulin aspart is excreted in human milk. Many drugs, including
- 439 human insulin, are excreted in human milk. For this reason, caution should be exercised when
- NovoLog is administered to a nursing mother. 440 441

#### **Pediatric Use** 442

- 443 Safety and effectiveness of NovoLog in children have not been studied.
- 444 445

#### 446 (Geriatric Use)

- 447 Of the total number of patients (n= 1,375) treated with NovoLog in 3 human insulin-controlled
- clinical studies, 2.6% (n=36) were 65 years of age or over. Half of these patients had Type 1
- diabetes (18/1285) and half had Type 2 (18/90) diabetes. The HbA1c response to
- 450 NovoLog, as compared to human insulin, did not differ by age, particularly in patients with
- 451 Type 2 diabetes. Additional studies in larger populations of patients 65 years of age or over
- are needed to permit conclusions regarding the safety of NovoLog in elderly compared to
- 453 younger patients. Pharmacokinetic/pharmacodynamic studies to assess the effect of age on the
- 454 onset of NovoLog action have not been performed.
- 455 456

# 457 **ADVERSE REACTIONS**

- 458 Clinical trials comparing NovoLog with regular human insulin did not demonstrate a
- 459 difference in frequency of adverse events between the two treatments.
- 460 Adverse events commonly associated with human insulin therapy include the following:
- 461 Body as Whole Allergic reactions (see PRECAUTIONS, Allergy).
- 462 Skin and Appendages Injection site reaction, lipodystrophy, pruritus, rash (see
- 463 PRECAUTIONS, Allergy; Information for Patients, Usage in Pumps).
- 464 **Other** Hypoglycemia, Hyperglycemia and ketosis (see WARNINGS and
- 465 PRECAUTIONS).
- 466 In controlled clinical trials, small, but persistent elevations in alkaline phosphatase result were
- d67 observed in some patients treated with NovoLog. The clinical significance of this finding isunknown.
- 469

# 470 OVERDOSAGE

- 471 Hypoglycemia may occur as a result of an excess of insulin relative to food intake, energy
- 472 expenditure, or both. Mild episodes of hypoglycemia usually can be treated with oral glucose.
- 473 Adjustments in drug dosage, meal patterns, or exercise, may be needed. More severe episodes
- with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous
- 475 glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation
- 476 may be necessary because hypoglycemia may recur after apparent clinical recovery.
- 477

### 478 DOSAGE AND ADMINISTRATION

- 479 NovoLog should generally be given immediately before a meal (start of meal within 5-10
- 480 minutes after injection) because of its fast onset of action. The dosage of
- 481 NovoLog should be individualized and determined, based on the physician's advice, in
- 482 accordance with the needs of the patient. The total daily individual insulin requirement is
- usually between 0.5-1.0 units/kg/day. When used in a meal-related subcutaneous injection
- treatment regimen, 50-70% of total insulin requirements may be provided by NovoLog and the
- remainder provided by an intermediate-acting or long-acting insulin. When used in external
- insulin infusion pumps, the initial programming of the pump is based on the total daily insulin
- 487 dose of the previous regimen. Although there is significant interpatient variability,
- 488 approximately 50% of the total dose is given as meal-related boluses of NovoLog and the
- remainder as basal infusion. Because of NovoLog's comparatively rapid onset and short
- 490 duration of glucose lowering activity, some patients may require more basal insulin and more

- 491 total insulin to prevent pre-meal hyperglycemia when using NovoLog than when using human
- 492 regular insulin. Additional basal insulin injections, or higher basal rates in external
- subcutaneous infusion pumps may be necessary. Infusion sets and the insulin in the infusion
- 494 sets must be changed every 48 hours or sooner to assure the activity of NovoLog and
- 495 proper pump function. (See WARNINGS, PRECAUTIONS, Information for Patients)
- 496
- 497 NovoLog should be administered by subcutaneous injection in the abdominal wall, the thigh,
- or the upper arm, or by continuous subcutaneous infusion in the abdominal wall. Injection
- sites and infusion sites should be rotated within the same region. As with all insulins, the
- 500 duration of action will vary according to the dose, injection site, blood flow, temperature, and 501 level of physical activity.
- 502 Parenteral drug products should be inspected visually for particulate matter and discoloration
- 503 prior to administration, whenever solution and container permit. Never use any NovoLog if it
- has become viscous (thickened) or cloudy; use it only if it is clear and colorless. NovoLog
- should not be used after the printed expiration date.

#### 506 507 HOW SUPPLIED

- NovoLog is available in the following package sizes: each presentation containing 100 Units
- of insulin aspart per mL (U-100).
- 510 10 mL vials NDC 0169-7501-11
- 511 3 mL PenFill<sup>®</sup> cartridges\* NDC 0169-3303-12
- 512 3 mL NovoLog FlexPen® Prefilled syringe NDC 0169-6339-10
- 513
- <sup>514</sup> \* NovoLog PenFill cartridges are for use with NovoFine<sup>®</sup> disposable needles and the
- following 3 mL PenFill cartridge compatible delivery devices: NovoPen<sup>®</sup>3, NovoPen Junior,
   Innovo<sup>®</sup> and InDuo<sup>®</sup>.
- 517 NovoLog FlexPen Prefilled syringes are for use with NovoFine disposable needles.
- 518

# 519 **RECOMMENDED STORAGE**

- 520 NovoLog in unopened vials, cartridges, and NovoLog FlexPen Prefilled syringes should be
- stored between 2° and 8°C (36° to 46°F). *Do not freeze*. **Do not use NovoLog if it has been**
- 522 frozen or exposed to temperatures that exceed 37°C (98.6°F). After a vial or cartridge has
- 523 been punctured, it may be kept at temperatures below 30°C (86°F) for up to 28 days, but
- should not be exposed to excessive heat or sunlight. Opened vials may be refrigerated.
- 525 Cartridges should not be refrigerated after insertion into the NovoPen 3. Infusion sets
- 526 (reservoirs, tubing, and catheters) and the NovoLog in the reservoir should be discarded after
- 527 no more than 48 hours of use or after exposure to temperatures that exceed  $37^{\circ}C$  (98.6°F).
- 528
- 529 Rx only
- 530
- 531 Date of Issue: [date]
- 532 8-XXXX-XX-XXX-X
- 533
- 534 Manufactured For Novo Nordisk Pharmaceuticals, Inc.
- 535 Princeton, New Jersey 08540

- 536
- Manufactured By Novo Nordisk A/S 537
- 538 2880 Bagsvaerd, Denmark
- 539 www.novonordisk-us.com
- 540
- NovoLog<sup>®</sup>, Novolin<sup>®</sup>, Velosulin<sup>®</sup>, PenFill<sup>®</sup>, FlexPen<sup>®</sup>, NovoFine<sup>®</sup>, NovoPen<sup>®</sup>, and Innovo<sup>®</sup> 541
- are trademarks of Novo Nordisk A/S 542
- 543
- 544
- 545
- H-TRON<sup>®</sup> is a trademark of Disetronic Medical Systems, Inc. Polyfin<sup>®</sup> and Sof-set<sup>®</sup> are trademarks of Medtronic MiniMed, Inc. InDuo<sup>®</sup> is a trademark of LifeScan, Inc., a Johnson & Johnson company. 546

Novo Nordisk submission date: 3/5/04